GNCA Short Information, Genocea Biosciences Inc.

Twenty Trading Day Totals
Total Shorted Volume	1,353,777
Total Actual Volume	7,463,787

Averages
Average Short Volume	67,689
Average Short Percentage	47.00%

Is there a GNCA Short Squeeze or Breakout about to happen?

See the GNCA Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2020-05-22	2.63	2.81	2.85	2.5	445,845	71,509	52.0520
2020-05-21	2.49	2.58	2.7	2.49	579,082	72,927	28.4665
2020-05-20	2.42	2.51	2.55	2.42	322,631	48,856	46.5894
2020-05-19	2.55	2.41	2.55	2.38	497,855	112,778	55.0118
2020-05-18	2.57	2.45	2.64	2.4	443,254	93,564	51.8087
2020-05-15	2.54	2.53	2.78	2.5	374,815	59,953	40.4620
2020-05-14	2.75	2.54	2.785	2.36	576,193	104,090	41.8150
2020-05-13	2.92	2.65	2.95	2.4	1,031,375	248,190	60.9034
2020-05-12	2.5	2.7	2.72	2.315	373,245	67,595	49.5474
2020-05-11	2.23	2.44	2.54	2.2	392,202	51,523	32.8352
2020-05-08	2.36	2.2	2.3754	2.1	207,741	27,689	34.2152
2020-05-07	2.29	2.36	2.51	2.26	588,722	102,566	51.0154
2020-05-06	2.39	2.24	2.39	2.22	100,228	14,095	36.1262
2020-05-05	2.37	2.3	2.4397	2.27	192,694	26,886	50.6566
2020-05-04	2.2	2.33	2.38	2.1799	173,631	26,451	60.0163
2020-05-01	2.34	2.24	2.3575	2.2	105,490	18,574	47.3500
2020-04-30	2.4	2.28	2.4	2.01	315,833	63,310	53.4550
2020-04-29	2.31	2.25	2.41	2.21	206,577	49,752	61.5834
2020-04-28	2.4	2.23	2.42	2.2	256,095	57,668	51.8592
2020-04-27	2.11	2.31	2.39	2.11	280,279	35,801	34.2168

Stock Information

Genocea Biosciences Inc. Company Name:

GNCA Stock Symbol:

NASDAQ Market:

Genocea Biosciences Inc. Website:

GNCA Short Information, Genocea Biosciences Inc.

Get GNCA Alerts

News, Short Squeeze, Breakout and More Instantly...

RECENT GNCA NEWS

GNCA - BIDU, UAL among premarket gainers

Dynavax Technologies (NASDAQ: DVAX ) +41% as COVID-19 vaccine trial could start as soon as July. More news on: Dynavax Technologies Corporation, Arbutus Biopharma Corporation, cbdMD, Inc., Stocks on the move, , Read more ...
GNCA - Genocea teams up with Shionogi to develop herpes vaccine

Genocea Biosciences (NASDAQ: GNCA ) inks a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. ( OTCPK:SGIOY ) to develop a novel herpes simplex virus type 2 (HSV-2) vaccine. More news on: Genocea Biosciences, Inc., Shionogi & Co., Ltd., Healt...
GNCA - Genocea Announces Material Transfer and License Option Agreement with Shionogi for Proprietary GEN-003 HSV-2 Antigens

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shion...